TW202214211A - 肉毒桿菌毒素用於治療臉部皺紋的用途及治療臉部皺紋的方法 - Google Patents
肉毒桿菌毒素用於治療臉部皺紋的用途及治療臉部皺紋的方法 Download PDFInfo
- Publication number
- TW202214211A TW202214211A TW110120421A TW110120421A TW202214211A TW 202214211 A TW202214211 A TW 202214211A TW 110120421 A TW110120421 A TW 110120421A TW 110120421 A TW110120421 A TW 110120421A TW 202214211 A TW202214211 A TW 202214211A
- Authority
- TW
- Taiwan
- Prior art keywords
- units
- botulinum toxin
- lines
- treatment
- frown
- Prior art date
Links
- 108030001720 Bontoxilysin Proteins 0.000 title claims abstract description 129
- 230000037303 wrinkles Effects 0.000 title claims abstract description 123
- 229940053031 botulinum toxin Drugs 0.000 title claims abstract description 116
- 230000001815 facial effect Effects 0.000 title claims abstract description 102
- 238000011282 treatment Methods 0.000 title claims abstract description 96
- 238000000034 method Methods 0.000 title claims abstract description 19
- 206010040954 Skin wrinkling Diseases 0.000 claims abstract description 186
- 239000007924 injection Substances 0.000 claims abstract description 104
- 238000002347 injection Methods 0.000 claims abstract description 104
- 108010057266 Type A Botulinum Toxins Proteins 0.000 claims description 34
- 239000002581 neurotoxin Substances 0.000 claims description 30
- 231100000618 neurotoxin Toxicity 0.000 claims description 30
- 210000004709 eyebrow Anatomy 0.000 claims description 27
- 101710138657 Neurotoxin Proteins 0.000 claims description 24
- 210000001061 forehead Anatomy 0.000 claims description 16
- 231100001103 botulinum neurotoxin Toxicity 0.000 claims description 12
- 231100000189 neurotoxic Toxicity 0.000 claims description 11
- 230000002887 neurotoxic effect Effects 0.000 claims description 11
- 239000007927 intramuscular injection Substances 0.000 claims description 2
- 238000010255 intramuscular injection Methods 0.000 claims description 2
- 230000002093 peripheral effect Effects 0.000 claims description 2
- 235000004252 protein component Nutrition 0.000 claims description 2
- 239000000243 solution Substances 0.000 abstract description 5
- 210000003205 muscle Anatomy 0.000 description 51
- 230000000694 effects Effects 0.000 description 38
- 108010024001 incobotulinumtoxinA Proteins 0.000 description 31
- 230000006872 improvement Effects 0.000 description 26
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 23
- 239000002537 cosmetic Substances 0.000 description 23
- 229940094657 botulinum toxin type a Drugs 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 108090000623 proteins and genes Proteins 0.000 description 17
- 230000004044 response Effects 0.000 description 17
- 239000003053 toxin Substances 0.000 description 17
- 231100000765 toxin Toxicity 0.000 description 17
- 108700012359 toxins Proteins 0.000 description 17
- 230000008859 change Effects 0.000 description 15
- 230000002411 adverse Effects 0.000 description 13
- 239000000203 mixture Substances 0.000 description 13
- 239000011780 sodium chloride Substances 0.000 description 13
- 102000008100 Human Serum Albumin Human genes 0.000 description 9
- 108091006905 Human Serum Albumin Proteins 0.000 description 9
- 108010079650 abobotulinumtoxinA Proteins 0.000 description 9
- 231100000252 nontoxic Toxicity 0.000 description 9
- 230000003000 nontoxic effect Effects 0.000 description 9
- 229940037201 oris Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 7
- 229940089093 botox Drugs 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 231100000673 dose–response relationship Toxicity 0.000 description 6
- 238000009472 formulation Methods 0.000 description 6
- 239000012895 dilution Substances 0.000 description 5
- 238000010790 dilution Methods 0.000 description 5
- 230000002500 effect on skin Effects 0.000 description 5
- 239000000945 filler Substances 0.000 description 5
- 231100000636 lethal dose Toxicity 0.000 description 5
- 230000003472 neutralizing effect Effects 0.000 description 5
- 229940018272 xeomin Drugs 0.000 description 5
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 206010033546 Pallor Diseases 0.000 description 4
- 239000007864 aqueous solution Substances 0.000 description 4
- 238000004166 bioassay Methods 0.000 description 4
- 238000009792 diffusion process Methods 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 229940068196 placebo Drugs 0.000 description 4
- 239000000902 placebo Substances 0.000 description 4
- 229940124272 protein stabilizer Drugs 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical group CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 3
- 206010067484 Adverse reaction Diseases 0.000 description 3
- 206010015995 Eyelid ptosis Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 241000225674 Procerus Species 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- 230000006838 adverse reaction Effects 0.000 description 3
- 230000000536 complexating effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 229940098753 dysport Drugs 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 239000000185 hemagglutinin Substances 0.000 description 3
- 229920002674 hyaluronan Polymers 0.000 description 3
- 229960003160 hyaluronic acid Drugs 0.000 description 3
- 229960004716 idoxuridine Drugs 0.000 description 3
- 230000005847 immunogenicity Effects 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 201000003004 ptosis Diseases 0.000 description 3
- 108010074523 rimabotulinumtoxinB Proteins 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 241000193155 Clostridium botulinum Species 0.000 description 2
- 208000020401 Depressive disease Diseases 0.000 description 2
- 108010085220 Multiprotein Complexes Proteins 0.000 description 2
- 102000007474 Multiprotein Complexes Human genes 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000003796 beauty Effects 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000000423 cell based assay Methods 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 230000005923 long-lasting effect Effects 0.000 description 2
- 150000002772 monosaccharides Chemical class 0.000 description 2
- 210000001640 nerve ending Anatomy 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000000946 synaptic effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 101710117542 Botulinum neurotoxin type A Proteins 0.000 description 1
- 101710082714 Exotoxin A Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 241000158526 Nasalis Species 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- RVGRUAULSDPKGF-UHFFFAOYSA-N Poloxamer Chemical compound C1CO1.CC1CO1 RVGRUAULSDPKGF-UHFFFAOYSA-N 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 229940077429 abobotulinumtoxina Drugs 0.000 description 1
- 108010069023 botulinum toxin type E Proteins 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000007385 chemical modification Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000008921 facial expression Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 238000009499 grossing Methods 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000010324 immunological assay Methods 0.000 description 1
- 230000030214 innervation Effects 0.000 description 1
- 239000002563 ionic surfactant Substances 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 229940112646 myobloc Drugs 0.000 description 1
- 230000002232 neuromuscular Effects 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229940077446 onabotulinumtoxina Drugs 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 229960000502 poloxamer Drugs 0.000 description 1
- 229920001983 poloxamer Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229950008882 polysorbate Drugs 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 230000037075 skin appearance Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 210000003699 striated muscle Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000007888 toxin activity Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/66—Enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/24—Metalloendopeptidases (3.4.24)
- C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
- A61K2800/91—Injection
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Birds (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Cosmetics (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20178574 | 2020-06-05 | ||
| EP20178574.8 | 2020-06-05 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TW202214211A true TW202214211A (zh) | 2022-04-16 |
Family
ID=71016459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW110120421A TW202214211A (zh) | 2020-06-05 | 2021-06-04 | 肉毒桿菌毒素用於治療臉部皺紋的用途及治療臉部皺紋的方法 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US12599550B2 (enExample) |
| EP (2) | EP4161562B1 (enExample) |
| JP (2) | JP2023529095A (enExample) |
| KR (1) | KR20230020961A (enExample) |
| CN (1) | CN115666629A (enExample) |
| AU (1) | AU2021286196A1 (enExample) |
| BR (1) | BR112022023413A2 (enExample) |
| CA (1) | CA3177835A1 (enExample) |
| ES (1) | ES3013130T3 (enExample) |
| IL (1) | IL298399A (enExample) |
| MX (1) | MX2022014564A (enExample) |
| TW (1) | TW202214211A (enExample) |
| WO (1) | WO2021245223A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL298399A (en) | 2020-06-05 | 2023-01-01 | Merz Pharma Gmbh & Co Kgaa | Treatment of facial wrinkles with the botulinum toxin in high dose and low volume |
| TWI852454B (zh) * | 2022-04-01 | 2024-08-11 | 大陸商重慶譽顏製藥有限公司 | 一種肉毒毒素蛋白組合物、製備方法及其應用 |
| KR20250113431A (ko) * | 2022-11-28 | 2025-07-25 | 메르츠 파마 게엠베하 운트 코. 카가아 | 목을 재생하기 위한 고 농도 보툴리눔 독소 치료 |
| WO2025231403A1 (en) * | 2024-05-03 | 2025-11-06 | Revivity Pharma Corporation | Methods of administering and manufacturing toxic compounds |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19925739A1 (de) | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
| US7691394B2 (en) * | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
| DE10333317A1 (de) | 2003-07-22 | 2005-02-17 | Biotecon Therapeutics Gmbh | Formulierung für Proteinarzneimittel ohne Zusatz von humanem Serumalbumin (HSA) |
| EP1786459B1 (en) | 2004-07-26 | 2014-02-12 | Merz Pharma GmbH & Co. KGaA | Therapeutic composition whit a botulinum neurotoxin |
| EP2072039A1 (en) * | 2007-12-21 | 2009-06-24 | Merz Pharma GmbH & Co.KGaA | Use of a neurotoxic component of Clostridium botulinum toxin complex to reduce or prevent side effects |
| MY155049A (en) | 2008-03-14 | 2015-08-28 | Allergan Inc | Immuno-based botolinum toxin serotype a activity assay |
| LT2761065T (lt) * | 2011-09-29 | 2018-01-10 | Cellsnap, Llc | Kompozicijos ir būdai toksigeniškumo testavimui |
| US11976110B2 (en) | 2013-06-28 | 2024-05-07 | Merz Pharma Gmbh & Co. Kgaa | Means and methods for the determination of the biological activity of neurotoxin polypeptides in cells |
| US9480731B2 (en) * | 2013-12-12 | 2016-11-01 | Medy-Tox, Inc. | Long lasting effect of new botulinum toxin formulations |
| RU2020121540A (ru) | 2017-12-04 | 2022-01-10 | Реванс Терапьютикс, Инк. | Инъецируемые составы ботулинического токсина и способы их применения с высокими показателями ответа и длительной продолжительностью эффекта |
| IL298399A (en) | 2020-06-05 | 2023-01-01 | Merz Pharma Gmbh & Co Kgaa | Treatment of facial wrinkles with the botulinum toxin in high dose and low volume |
-
2021
- 2021-06-04 IL IL298399A patent/IL298399A/en unknown
- 2021-06-04 EP EP21728601.2A patent/EP4161562B1/en active Active
- 2021-06-04 JP JP2022573504A patent/JP2023529095A/ja active Pending
- 2021-06-04 AU AU2021286196A patent/AU2021286196A1/en active Pending
- 2021-06-04 BR BR112022023413A patent/BR112022023413A2/pt unknown
- 2021-06-04 CN CN202180037805.1A patent/CN115666629A/zh active Pending
- 2021-06-04 KR KR1020227040449A patent/KR20230020961A/ko active Pending
- 2021-06-04 EP EP24206746.0A patent/EP4467202A3/en active Pending
- 2021-06-04 WO PCT/EP2021/064986 patent/WO2021245223A1/en not_active Ceased
- 2021-06-04 TW TW110120421A patent/TW202214211A/zh unknown
- 2021-06-04 CA CA3177835A patent/CA3177835A1/en active Pending
- 2021-06-04 ES ES21728601T patent/ES3013130T3/es active Active
- 2021-06-04 MX MX2022014564A patent/MX2022014564A/es unknown
- 2021-06-04 US US18/007,712 patent/US12599550B2/en active Active
-
2026
- 2026-01-20 US US19/453,776 patent/US20260144733A1/en active Pending
- 2026-02-06 JP JP2026018408A patent/JP2026077675A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4161562A1 (en) | 2023-04-12 |
| EP4467202A2 (en) | 2024-11-27 |
| KR20230020961A (ko) | 2023-02-13 |
| US20260144733A1 (en) | 2026-05-28 |
| JP2023529095A (ja) | 2023-07-07 |
| MX2022014564A (es) | 2022-12-15 |
| EP4161562B1 (en) | 2024-11-20 |
| WO2021245223A1 (en) | 2021-12-09 |
| CN115666629A (zh) | 2023-01-31 |
| EP4467202A3 (en) | 2025-02-19 |
| CA3177835A1 (en) | 2021-12-09 |
| AU2021286196A1 (en) | 2022-12-01 |
| ES3013130T3 (en) | 2025-04-11 |
| JP2026077675A (ja) | 2026-05-13 |
| US12599550B2 (en) | 2026-04-14 |
| IL298399A (en) | 2023-01-01 |
| US20230329996A1 (en) | 2023-10-19 |
| BR112022023413A2 (pt) | 2022-12-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12144847B2 (en) | Non-protein clostridial toxin compositions | |
| US12599550B2 (en) | High dose and low volume botulinum toxin treatment of facial wrinkles | |
| JP6955491B2 (ja) | 治療効果又は美容効果の長い持続時間を有する、注射用ボツリヌス毒素製剤及びこれらの使用方法 | |
| ES2880281T3 (es) | Nanoemulsiones de botulinum | |
| US20230158129A1 (en) | Clostridial toxin - hyaluronic acid compositions | |
| AU2017227978B2 (en) | Composition comprising botulinum toxin | |
| MX2014011376A (es) | Metodo de tratamiento de arrugas mediante agentes quimiodenervantes topicos. | |
| Boone et al. | Botulinum toxin in aesthetic medicine | |
| RU2835617C1 (ru) | Лечение морщин на лице высокой дозой и малым объемом ботулинического токсина | |
| JP2011157331A (ja) | 高用量投与が可能なボツリヌス毒素製剤 | |
| TW202435908A (zh) | 組成物及應用其之注射裝置 | |
| KR20230071072A (ko) | 보툴리눔 독소 조성물 | |
| HK40085901A (en) | High dose and low volume botulinum toxin treatment of facial wrinkles | |
| US20240207303A1 (en) | mNA-based Delivery of Botulinum Toxin | |
| US20240000905A1 (en) | Polymeric nanoparticle compositions for encapsulation and sustained release of neuromodulators | |
| KR20250113350A (ko) | 비-복합체 보툴리눔 독소 조성물의 빠른 효력 발현 효과 및 이와 관련된 방법 | |
| EP4626556A1 (en) | High concentration botulinum toxin treatment for neck rejuvenation |